Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jul;20(7):1298-304.
doi: 10.1038/mt.2012.79. Epub 2012 Apr 24.

In vivo gene delivery by nonviral vectors: overcoming hurdles?

Yuan Zhang  1 , Andrew Satterlee, Leaf Huang
Affiliations
Review

In vivo gene delivery by nonviral vectors: overcoming hurdles?

Yuan Zhang et al. Mol Ther. 2012 Jul.

Abstract

The promise of cancer gene therapeutics is hampered by difficulties in the in vivo delivery to the targeted tumor cells, and systemic delivery remains to be the biggest challenge to be overcome. Here, we concentrate on systemic in vivo gene delivery for cancer therapy using nonviral vectors. In this review, we summarize the existing delivery barriers together with the requirements and strategies to overcome these problems. We will also introduce the current progress in the design of nonviral vectors, and briefly discuss their safety issues.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative scheme of in vivo gene delivery barriers. EPR, enhanced permeability and retention; mRNA, messenger RNA; PEG, polyethylene glycol; RES, reticuloendothelial system; RISC, RNA-induced silencing complex; siRNA, small interfering RNA.
Figure 2
Figure 2
The structure and preparation scheme of LPD (LPD-II)/LPH nanoparticles. LPD, liposome-polycation-DNA; LPH, liposome-polycation-hyaluronic acid (or heparin); pDNA, plasmid DNA; PEG, polyethylene glycol; siRNA, small interfering RNA.
See this image and copyright information in PMC

References

    1. Elsabahy M, Nazarali A., and, Foldvari M. Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv. 2011;8:235–244. - PubMed
    1. Monaghan M., and, Pandit A. RNA interference therapy via functionalized scaffolds. Adv Drug Deliv Rev. 2011;63:197–208. - PubMed
    1. Vickers TA, Lima WF, Wu H, Nichols JG, Linsley PS., and, Crooke ST. Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 'Slicer' independent and can be mediated by Ago1. Nucleic Acids Res. 2009;37:6927–6941. - PMC - PubMed
    1. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M.et al. (2003Expression profiling reveals off-target gene regulation by RNAi Nat Biotechnol 21635–637. - PubMed
    1. Fedorov Y, King A, Anderson E, Karpilow J, Ilsley D, Marshall W.et al. (2005Different delivery methods-different expression profiles Nat Methods 2241. - PubMed

Publication types